Overview
PT-141 is classified as a melanocortin agonist peptide. Sexual arousal, libido.
Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
Also known as: Bremelanotide, Vyleesi
Category
Melanocortin Agonist
Half-Life
2.7h
Route
SubQ
FDA Status
Approved
How Does PT-141 Work?
Central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects.
At the molecular level, PT-141 operates through pathways characteristic of the Melanocortin Agonist class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]PT-141 (Bremelanotide) for hypoactive sexual desire Phase 3
Kingsberg et al. (Obstet. & Gynecol.): Two identical Phase 3 RECONNECT trials showing bremelanotide significantly improves sexual desire and reduces distress in premenopausal women with HSDD.
Evidence: very strong[2]Bremelanotide Phase 3 efficacy and safety in HSDD
Clayton et al.: Phase 3 data confirming statistically significant improvements in desire metrics with favorable safety profile (nausea, flushing, headache). Led to FDA approval.
Evidence: very strong[3]PT-141 induces erection in men with erectile dysfunction
Diamond et al.: Double-blind, placebo-controlled study showing PT-141 induces significant erectile response at >7mg doses, effective even in PDE5 inhibitor non-responders.
Evidence: strong[4]Bremelanotide mechanism of action and pharmacology review
Comprehensive review of bremelanotide's MC4R mechanism, pharmacokinetics, clinical trial efficacy, and safety data across male and female sexual dysfunction studies.
Evidence: strongSafety Profile
Nausea/hypertension possible. FDA-approved (Vyleesi) for HSDD in premenopausal women. Limited to 8 doses/month.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~40% of users | moderate |
| Flushing | ~20% of users | mild |
| Headache | ~10% of users | mild |
| Transient blood pressure increase | ~8% of users | moderate |
Sourcing PT-141 for Research
If you're looking to source PT-141 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
PT-141 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.